American Society of Hematology

Figure 1.

$Figure 1. NK-cell number, phenotype and function in the first year posttransplant for patients treated with haploidentical stem cell transplantation using posttransplant cyclophosphamide on protocol 2009-0266 (without NK-cell infusions). (A) Absolute lymphocyte count (ALC) was determined from a clinical complete blood count obtained at the indicated time point. (B) Absolute NK-cell counts were determined from PB samples obtained at same time points, from which PBMCs were isolated and cryopreserved for batch testing. CD3−CD56+ populations were determined from within lymphocyte gates, and absolute NK count derived according to the percent of CD3−CD56+ cells. (C) NK-cell maturity was determined according to CD16+ and CD16− fractions of the NK cells in Figure 3B. (D) NK-cell function at 1 month posttransplant was determined by measuring cytotoxicity against 721.221 targets, wherein PBMCs were applied according to NK-cell content at a 40:1 NK-to-target ratio.$

NK-cell number, phenotype and function in the first year posttransplant for patients treated with haploidentical stem cell transplantation using posttransplant cyclophosphamide on protocol 2009-0266 (without NK-cell infusions). (A) Absolute lymphocyte count (ALC) was determined from a clinical complete blood count obtained at the indicated time point. (B) Absolute NK-cell counts were determined from PB samples obtained at same time points, from which PBMCs were isolated and cryopreserved for batch testing. CD3⁻CD56⁺ populations were determined from within lymphocyte gates, and absolute NK count derived according to the percent of CD3⁻CD56⁺ cells. (C) NK-cell maturity was determined according to CD16⁺ and CD16⁻ fractions of the NK cells in Figure 3B. (D) NK-cell function at 1 month posttransplant was determined by measuring cytotoxicity against 721.221 targets, wherein PBMCs were applied according to NK-cell content at a 40:1 NK-to-target ratio.

This Feature Is Available To Subscribers Only